Correlation Between Entera Bio and Lyra Therapeutics

Can any of the company-specific risk be diversified away by investing in both Entera Bio and Lyra Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entera Bio and Lyra Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entera Bio and Lyra Therapeutics, you can compare the effects of market volatilities on Entera Bio and Lyra Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entera Bio with a short position of Lyra Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entera Bio and Lyra Therapeutics.

Diversification Opportunities for Entera Bio and Lyra Therapeutics

0.55

Correlation Coefficient

Entera Bio  Lyra Therapeutics

Very weak diversification

The 3 months correlation between Entera and Lyra is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Entera Bio and Lyra Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyra Therapeutics and Entera Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entera Bio are associated (or correlated) with Lyra Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyra Therapeutics has no effect on the direction of Entera Bio i.e., Entera Bio and Lyra Therapeutics go up and down completely randomly.

Pair Corralation between Entera Bio and Lyra Therapeutics

Given the investment horizon of 90 days Entera Bio is expected to generate 0.52 times more return on investment than Lyra Therapeutics. However, Entera Bio is 1.94 times less risky than Lyra Therapeutics. It trades about -0.04 of its potential returns per unit of risk. Lyra Therapeutics is currently generating about -0.04 per unit of risk. If you would invest  188.00  in Entera Bio on September 4, 2024 and sell it today you would lose (20.00) from holding Entera Bio or give up 10.64% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Entera Bio  vs.  Lyra Therapeutics

Entera Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Lyra Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Entera Bio and Lyra Therapeutics

The main advantage of trading using opposite Entera Bio and Lyra Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entera Bio position performs unexpectedly, Lyra Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyra Therapeutics will offset losses from the drop in Lyra Therapeutics' long position.

The idea behind Entera Bio and Lyra Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.